Professor Maureen R. Hanson of the Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York, has looked into historical outbreaks of myalgic encephalomyelitis (ME), also known as chronic fatigue ...
Research led by Rockefeller University in New York investigated alternate targets for monoclonal antibodies to combat SARS-CoV-2 infections.
After three years of infections, lockdowns, and vaccinations, we know a lot about SARS-CoV-2, the virus that causes COVID-19—but we don't know everything. Like, why are some variants weaker than others? Why does the omicron ...
Jan 11, 2023
2
73
A team of researchers at the University of Pennsylvania, working with a colleague from the University of Texas Medical Branch and another from Boston University and Boston Medical Center, has found that the SARS-CoV-2 virus ...
A team of researchers affiliated with several institutions in Brazil has found evidence of the SARS-CoV-2 virus infecting astrocyte cells in the human brain. In their paper published in Proceedings of the National Academy ...
A team of researchers at Institut Pasteur reports evidence that suggests the SARS-CoV-2 virus is able to enter the brain by using nose cells to make nanotube tunnels. In their paper published in the journal Science Advances, ...
A team of researchers with members from the Gladstone Institute and Curative Inc. has uncovered new attributes of the SARS-CoV-2 omicron variant that could explain why it is so much more transmissible than other variants ...
How does SARS-CoV-2 evade our immune defenses? It's a good question, actually. When SARS-CoV-2 defeats host defenses, we need to know how it does so, and conversely, when host defenses prevail, that also needs to be understood. ...
Important differences in how the nasal cells of young and elderly people respond to the SARS-CoV-2 virus, could explain why children typically experience milder COVID-19 symptoms, finds a new study led by researchers at UCL ...
Apr 15, 2024
0
77
A newly developed intranasal vaccine candidate helps to clear COVID-19 infections more quickly than controls in pre-clinical testing, according to a recent study. The new vaccine platform relies on a protein scaffold that ...
Mar 13, 2024
0
89
